Ventyx Biosciences, Inc.

Eli Lilly and Company

Shares of Ventyx Biosciences, a small-cap developer of anti-inflammatory drugs, jumped nearly 70% in early trading on Wednesday, January 7, after the <i>Wall Street Journal</i> <a href="https://www.wsj.com/health/pharma/eli-lilly-nears-deal-for-biotech-ventyx-3bc666d2">reported</a>&nbsp;that Eli Lilly is in talks to acquire the biotech.

Small biotech Ventyx soars 70% amid 'advanced talks' with Eli Lilly to be acquired

Novo Nordisk A/S

Viking Therapeutics, Inc.

The best-selling drug from Danish pharmaceutical giant Wegovy is now available in oral form for the first time.

Novo impressed investors by launching a weight loss pill in the US. What are its competitors doing?

The Danish company's shares have halved in price in 2025 amid doubts about its ability to conquer the market

First obesity pill: US approves Novo drug, how will the market react?

Novartis AG

Roche Holding AG

Amgen Inc.

Companies will get a three-year reprieve from pharmaceutical duties, provided they invest in manufacturing within the U.S.

Nine major pharma companies have made deals with Trump to lower drug prices

They are different from the already-hit Wegovy and Zepbound

Lilly and Novo simultaneously filed applications for approval of new obesity drugs

Late-stage trial data also show a potent effect in knee osteoarthritis

Eli Lilly's new drug has helped you lose almost 30% of your weight. It's her weapon of choice against Ozempic

Structure Therapeutics Inc.

Shares of Structure Therapeutics more than doubled on Monday, December 8, closing near $70 apiece, with <a href="https://finance.yahoo.com/quote/GPCR/">the company’s market capitalization</a> rocketing above $4.2 billion. This followed mid-stage trial results for its experimental oral obesity drug, aleniglipron, which <a href="https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-access">delivered</a>&nbsp;greater weight loss than a <a href="https://lilly.mediaroom.com/2025-08-07-Lillys-oral-GLP-1,-orforglipron,-delivers-weight-loss-of-up-to-an-average-of-27-3-lbs-in-first-of-two-pivotal-Phase-3-trials-in-adults-with-obesity">competing pill</a> under development by Eli Lilly. Analysts say the stock may have further upside, particularly if a major player moves to acquire the company.

Structure shares double after 'near-homerun' obesity pill data

Bank of America reaffirmed its "buy" recommendation for shares of pharmaceutical company Eli Lilly and raised the target forecast for its securities from $950 to $1286, CNBC <a href="https://www.cnbc.com/2025/12/02/bank-of-america-hikes-eli-lilly-price-target-on-promising-drug-pipeline.html">reports</a>. This estimate assumes growth of about 22% from the current figures.

"Confident Leadership. Bank of America expects Eli Lilly shares to grow by more than 20%

Merck & Co., Inc.

Regeneron Pharmaceuticals, Inc.

Increased volatility and doubts about AI's prospects have pushed the market toward defensive stocks

Healthcare has become a safe haven for investors: the sector grew by 10% in November

Novo Nordisk reported that its new experimental drug helped people lose weight and improve blood sugar levels in trials. The positive news contributed to the growth of the company's quotations by almost 5%. However, the shares of the Ozempic manufacturer have fallen in price by about 50% this year. Is it worth buying them in hopes of a reversal?

A new drug from the creator of Ozempic has helped people lose weight. Is it time to buy stocks?

The company is starting to resemble the tech giants from "The Magnificent Seven" again, analysts said

Eli Lilly became the first pharma giant to be capitalized at $1 trillion. What's next?

Hims & Hers Health, Inc.

The company is vying for a market that is predicted to grow to $100 billion by the end of the decade